Stay updated on MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Sign up to get notified when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.

Latest updates to the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe Publications section now includes a note that items are automatically filled from PubMed. The revision tag updates from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedThe government funding lapse notice has been removed from the page, and this does not affect the study details or core content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check49 days agoChange DetectedSubstantive study details (eligibility criteria, interventions, primary/secondary outcomes, and locations) appear unchanged. Minor formatting differences observed do not affect the content.SummaryDifference0.4%

- Check71 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference2%

- Check78 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes provided.SummaryDifference0.0%

- Check92 days agoChange DetectedUpdated the page revision to v3.0.2 from v3.0.1 and removed the 'Back to Top' element. No core content, pricing, or availability changes.SummaryDifference0.1%

Stay in the know with updates to MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.